Treatment paradigm shifting for men with prostate cancer
AuntMinnie
JUNE 28, 2024
New imaging and treatment strategies are emerging to prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC), according to a presentation at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. For instance, one emerging question is how new radionuclide treatments like lutetium-177 prostate-specific membrane antigen-617 (Lu-177 PSMA-617, Pluvicto ) will affect the use of existing ones such as radium-223 dichloride (Ra-223, Xofigo )
Let's personalize your content